Durvalumab (anti-PD-L1)

製品コードA2013 別名: MEDI4736 Non-humanized mouse model applicable

For research use only. Not for use in humans.

Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

サイズ 価格(税別)  
JPY 117362.00

質量管理及び製品安全説明書

PD-1/PD-L1阻害剤の選択性比較

生物活性

製品説明 Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
ターゲット
PD-L1/CD80 [1]
(HTRF assay)
PD-1/PD-L1 interaction [1]
(HTRF assay)
0.04 nM 0.1 nM
体外試験

Durvalumab (anti-PD-L1) is a potent antagonist of PD-L1 function, blocking interaction with PD-1 and CD80 to overcome inhibition of primary human T-cell activation. It does not trigger antibody-dependent cellular cytotoxicity (ADCC)[2].

体内試験 In vivo MEDI4736 significantly inhibits the growth of human tumors in a novel xenograft model containing coimplanted human T cells[2]. In patients with advanced solid tumors, The linear clearance, volume of distribution and concentration at half maximal elimination (KM) of MEDI4736 are 240 mL/day, 3.6 L and 0.4 μg/mL, respectively. The half-life is ~23 days at doses ≥ 3 mg/kg Q2W. Greater than 99% target saturation (soluble and membrane bound) is expected at ≥40 μg/mL of MEDI4736[3].

お薦めの試験操作(参考用のみ)

製品説明

Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store at -80°C and avoid freeze-thaw cycles.

技術サポート

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須
Tags: Durvalumab (anti-PD-L1)を買う | Durvalumab (anti-PD-L1) ic50 | Durvalumab (anti-PD-L1)供給者 | Durvalumab (anti-PD-L1)を購入する | Durvalumab (anti-PD-L1)費用 | Durvalumab (anti-PD-L1)生産者 | オーダーDurvalumab (anti-PD-L1) | Durvalumab (anti-PD-L1)化学構造 | Durvalumab (anti-PD-L1)分子量 | Durvalumab (anti-PD-L1)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID